Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Endrika Hinton

Reproductive Endocrinology Lutherville, MD Medical Doctor

NPI 1477561579 CMS profile 66871

10749 Falls Rd, Ste 302, Lutherville, MD 21093

Open in the dashboard

General payments

$4,048

221 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Endrika Hinton of Lutherville, MD is reported in the CMS Open Payments database as having received $4,048 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78 3
2024 General $20 1
2023 General $498 20
2022 General $1,130 54
2021 General $1,002 68
2020 General $692 41
2019 General $627 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Endrika Hinton
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Endrika Hinton were reported at $78. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Endrika Hinton Reproductive Endocrinology median Middle half National median
2019 $627 $196 $77–$425 $163
2020 $692 $81 $35–$182 $114
2021 $1,002 $102 $43–$247 $132
2022 $1,130 $139 $62–$303 $149
2023 $498 $141 $65–$285 $160
2024 $20 $144 $65–$302 $164
2025 $78 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $714 52 payments
  2. Ferring Pharmaceuticals Inc. $498 26 payments
  3. Exeltis, USA Inc. $433 24 payments
  4. TherapeuticsMD, Inc. $377 23 payments
  5. Mayne Pharma Inc. $235 9 payments
  6. Myovant Sciences Inc. $214 10 payments
  7. Evofem Biosciences, Inc. $151 10 payments
  8. Ferring Pharmaceuticals AS $127 1 payment
  9. Millicent US Inc $107 7 payments
  10. Baxter Healthcare $100 3 payments
  11. Other $1,091 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,898 215 payments
  2. Education $150 6 payments
Products named General payments · program years 2019–2025
  1. MENOPUR $428 22 payments
  2. LO LOESTRIN FE $396 34 payments
  3. SLYND $342 19 payments
  4. MYFEMBREE $259 12 payments
  5. ANNOVERA $230 14 payments
  6. IMVEXXY $230 14 payments
  7. ORILISSA $180 13 payments
  8. ORIAHNN $162 12 payments
  9. Phexxi $151 10 payments
  10. FEMRING $107 7 payments
  11. Other $1,732 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

120

Median for Obstetrics & Gynecology: 65

Drug cost

$9,411

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

78.3%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol (Twice Weekly) Estradiol Brand 31 $3,150
Estradiol Generic 26 $1,740
Estradiol-Norethindrone Acetat Estradiol/Norethindrone Acet Brand 11 $1,405
Estradiol (Once Weekly) Estradiol Brand 12 $1,340
Dotti Estradiol Brand 14 $912
Progesterone Progesterone, Micronized Brand 26 $864

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$1,307

Medicare's payments for the services billed

Medicare patients

24

Average age 70

Services billed

29

24 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 63%
Heart failure 0%
Chronic kidney disease 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record